The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement

Gouill, Steven Le; Talmant, Pascaline; Touzeau, Cyrille; Moreau, Anne; Garand, Richard; Juge‐Morineau, Nadine; Gaillard, Fanny; Gastinne, Thomas; Milpied, Noël; Moreau, Philippe; Harousseau, Jean Luc; Avet-Loiseau, Hervé

doi:10.3324/haematol.11305

Cited by 198 publications

(157 citation statements)

References 39 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…Most cases of DLBCL with t(14;18) and 8q24 translocations are classified as GCB-type DLBCL because many DLBCL patients with dual translocation are CD10-positive. Our findings and other studies 7,8 do not confirm this result in the subgroup of DLBCL with t(14;18) and 8q24 translocations. The 5-year OS of patients with GCB-type DLBCL was 78% compared with 15% among those with non-GCB DLBCL.…”

Section: Tablecontrasting

confidence: 56%

“…The results of this study may be useful when deciding the treatment strategy in patients with dual translocation. The report of Le Gouill et al 7 also showed very poor prognosis of patients with the dual translocation of t(14;18) and 8q24/c-MYC, with a median PFS of 4 months and OS of 5 months. We administered rituximab combination chemotherapy in six patients in this study.…”

Section: Tablementioning

confidence: 99%

“…6 In recent years, patients with DLBCL with concurrent t(14;18)(q32;q21) and 8q24 translocations have been reported. 7,8 Le Gouill et al 7 reported 16 cases of DLBCL with t(14;18) and 8q24 translocations. In their report, DLBCL with t(14;18) and 8q24 translocations showed germinal center profile in all cases and a poor outcome.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

Niitsu

Okamoto²,

Miura³

et al. 2009

Leukemia

209

181

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) having both t(14;18) and 8q24 translocations is rare. We evaluated the clinical characteristics and prognoses of patients with DLBCL carrying both t(14;18) and 8q24 translocations. A total of 1972 patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group (ALTSG) from 1998 to 2007. Nineteen cases of de novo DLBCL with the dual translocation were identified. The dual translocation was observed in 19 of 394 patients with DLBCL (10 males and 9 females, with a median age of 61 years). The dual translocation was observed significantly more frequently among patients with high lactate dehydrogenase levels, B symptoms, bone marrow involvement and advanced stage. Immunophenotyping was performed and showed DLBCL with a germinal center type in the majority of cases. Progression-free survival and overall survival rates were significantly lower in patients with the dual translocation than in those with other translocation. DLBCL patients with concurrent t(14;18) and 8q24 translocations have very poor prognosis. Even if patients had a complete response to chemotherapy, they subsequently suffered early relapse. In this study, only a few patients received rituximab, and its usefulness could not be assessed. Future studies with larger numbers of patients are required.

show abstract

Section: Tablecontrasting

confidence: 56%

Section: Tablementioning

confidence: 99%

See 1 more Smart Citation

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

Niitsu

Okamoto²,

Miura³

et al. 2009

Leukemia

209

181

View full text Add to dashboard Cite

show abstract

“…33 Regions for CD10 analysis were carefully drawn to exclude germinal centres within lymphoid follicles as some immature T and B precursors, as well as proliferating B cells and mature neutrophils, may weakly express CD10. 34 Remaining CD10þ cells displayed morphology and size consistent with endometrial stromal cells rather than lymphocytes.…”

Section: Quantificationmentioning

confidence: 99%

Endometrial Stromal Cells and Immune Cell Populations Within Lymph Nodes in a Nonhuman Primate Model of Endometriosis

et al. 2011

View full text Add to dashboard Cite

Mounting evidence suggests that immunological responses may be altered in endometriosis. The baboon (Papio anubis) is generally considered the best model of endometriosis pathogenesis. The objective of the current study was to investigate for the first time immunological changes within uterine and peritoneal draining lymph nodes in a nonhuman primate baboon model of endometriosis. Paraffin-embedded femoral lymph nodes were obtained from 22 normally cycling female baboons (induced endometriosis n ¼ 11; control n ¼ 11). Immunohistochemical staining was performed with antibodies for endometrial stromal cells, T cells, immature and mature dendritic cells, and B cells. Lymph nodes were evaluated using an automated cellular imaging system. Endometrial stromal cells were significantly increased in lymph nodes from animals with induced endometriosis, compared to control animals (P ¼ .033). In animals with induced endometriosis, some lymph node immune cell populations including T cells, dendritic cells and B cells were increased, suggesting an efficient early response or peritoneal drainage.

show abstract

“…[4][5][6][7][8][9][10][11][12][13][14] Numerous case series of MYC/BCL2 double-hit lymphoma are reported in the literature. [15][16][17][18][19][20][21][22][23][24] MYC/ BCL2 DHLs represent B10% of all lymphomas that otherwise resemble diffuse large B-cell lymphoma (DLBCL). 10 Although different studies have focused on different aspects or details of double-hit lymphoma, all studies suggest that patients with these lymphomas commonly have an aggressive clinical course characterized by advanced stage disease, extranodal involvement, and high serum lactate dehydrogenase levels.…”

mentioning

confidence: 99%

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas

Seegmiller

Lin

et al. 2015

Modern Pathology

View full text Add to dashboard Cite

Large B-cell lymphomas with IGH@BCL2 and MYC rearrangement, known as double-hit lymphoma (DHL), are clinically aggressive neoplasms with a poor prognosis. Some large B-cell lymphomas have concurrent abnormalities of MYC and BCL2 other than coexistent translocations. Little is known about patients with these lymphomas designated here as atypical DHL. We studied 40 patients of atypical DHL including 21 men and 19 women, with a median age of 60 years. Nine (23%) patients had a history of B-cell non-Hodgkin lymphoma. There were 30 diffuse large B-cell lymphoma (DLBCL), 7 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma, and 3 DLBCL with coexistent follicular lymphoma. CD10, BCL2, and MYC were expressed in 28/39 (72%), 33/35 (94%), and 14/20 (70%) cases, respectively. Patients were treated with standard (n ¼ 14) or more aggressive chemotherapy regimens (n ¼ 17). We compared the atypical DHL group with 76 patients with DHLand 35 patients with DLBCL lacking MYC and BCL2 abnormalities. The clinicopathologic features and therapies were similar between patients with atypical and typical DHL. The overall survival of patients with atypical double-hit lymphoma was similar to that of patients with double-hit lymphoma (P ¼ 0.47) and significantly worse than that of patients with DLBCL with normal MYC and BCL2 (P ¼ 0.02). There were some minor differences. Cases of atypical double-hit lymphoma more often have DLBCL morphology (Po0.01), less frequently expressed CD10 (Po0.01), and patients less often had an elevated serum lactate dehydrogenase level (P ¼ 0.01). In aggregate, these results support expanding the category of MYC/ BCL2 DHL to include large B-cell lymphomas with coexistent MYC and BCL2 abnormalities other than concurrent translocations.

show abstract

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement

Cited by 198 publications

References 39 publications

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

Endometrial Stromal Cells and Immune Cell Populations Within Lymph Nodes in a Nonhuman Primate Model of Endometriosis

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas

Contact Info

Product

Resources

About